Suchergebnisse - "Perrone, Francesco"

PubPharm (403)

101

A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice

enthalten in: JAMA oncology | 2017

von Perrone, F. | Di Maio, M. | Del Mastro, L.

102

enthalten in: Recenti progressi in medicina | 2017

von Perrone, F. | Addis, A. | Sinagra, G. | +1

103

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB) : A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

enthalten in: Gynecologic oncology | 2017

von Daniele, G. | Lorusso, D. | Scambia, G. | +20

104

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

enthalten in: Gynecologic oncology | 2017

von Daniele, G. | Lorusso, D. | Scambia, G. | +20

105

A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial

enthalten in: Lung cancer | 2017

von Morabito, A. | Daniele, G. | Costanzo, R. | +17

106

Unpleaseant news.

enthalten in: Recenti progressi in medicina | 2016

von Perrone, F. | Gallo, C.

107

Ethics in oncology : principles and responsibilities declared in the Italian Ragusa statement

enthalten in: Tumori | 2016

von Gori, S. | Pinto, C. | Caminiti, C. | +21

108

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer : predictive value of DNA-PK and phosphorylated ACC

enthalten in: Oncotarget | 2016

von Perrone, F. | Baldassarre, G. | Indraccolo, S. | +27

109

BEVERLY : Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer

enthalten in: Clinical lung cancer | 2016

von Gridelli, C. | Rossi, A. | Ciardiello, F. | +10

110

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer : a cohort study

enthalten in: The Lancet. Oncology | 2016

von Bagnoli, M. | Canevari, S. | Califano, D. | +25

CommentIn: Lancet Oncol. 2016 Aug;17 (8):1032-1033. - PMID 27402146